Abstract:Atherosclerosis research typically focuses on the evolution of intermediate or advanced atherosclerotic lesions rather than on prelesional stages of atherogenesis. Yet these early events may provide decisive leads on the triggers of the pathologic process, before lesions become clinically overt. Thereby, it is mandatory to consider extracellular lipoprotein deposition at this stage as the prerequisite of foam cell formation leading to a remarkable accumulation of LDL (Low Density Lipoproteins). As progression of atherosclerosis displays the characteristic features of a chronic inflammatory process on the one hand and native LDL lacks inflammatory properties on the other hand, the lipoprotein must undergo biochemical modification to become atherogenic. During the last 25 years, evidence was accumulated in support of a different concept on atherogenesis proposing that modification of native LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or eLDL) rather than oxidation and contending that the physiological events leading to macrophage uptake and reverse transport of eLDL first occur without inflammation (initiation with reversion). Preventing or reversing initial atherosclerotic lesions would avoid the later stages and therefore prevent clinical manifestations. This concept is in accordance with the response to retention hypothesis directly supporting the strategy of lowering plasma levels of atherogenic lipoproteins as the most successful therapy for atherosclerosis and its sequelae. Apart from but unquestionable closely related to this concept, there are several other hypotheses on atherosclerotic lesion initiation favoring an initiating role of the immune system ('vascular-associated lymphoid tissue' (VALT)), defining foam cell formation as a variant of lysosomal storage disease, relating to the concept of the inflammasome with crystalline cholesterol and/or mitochondrial DAMPs (damage-associated molecular patterns) being mandatory in driving arterial inflammation and, last but not least, pointing to miRNAs (micro RNAs) as pivotal players. However, direct anti-inflammatory therapies may prove successful as adjuvant components but will likely never be used in the absence of strategies to lower plasma levels of atherogenic lipoproteins, the key point of the perception that atherosclerosis is not simply an inevitable result of senescence. In particular, given the importance of chemical modifications for lipoprotein atherogenicity, regulation of the enzymes involved might be a tempting target for pharmacological research.

Advances in Research into Coronary Artery Atherosclerotic Plaque Regression

Mechanistic insights into the regression of atherosclerotic plaques

Atherosclerotic plaque stabilization and regression: a review of clinical evidence

The clinical relevance of the reversal of coronary atherosclerotic plaque

Atherosclerotic Plaque Regression: Fact or Fiction?

Reversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents

Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization

Metabolic changes with the occurrence of atherosclerotic plaques and the effects of statins

Research Advances in Mechanism of Flavonoids Against Atherosclerosis

The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy

Statin Treatment and Progression of Atherosclerotic Plaque Burden

Effect of statin therapy on the progression of coronary atherosclerosis

Review of Atherosclerosis Regression

Endogenous Pro-Resolving and Anti-Inflammatory Lipid Mediators: the New Hope of Atherosclerotic Diseases.

Biomarkers of Atherosclerotic Plaque Vulnerability and Their Clinical Significance

Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

New Progress in Early Diagnosis of Atherosclerosis

Atheroprotective Effects of Statins in Patients with Unstable Angina by Regulating the Blood-Borne Microrna Network

Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

[Novel therapy for atherosclerosis and inflammatory vascular disease]